FILE PHOTO: A surgery nurse is seen beside the heart beat monitor in the operating theatre of the Unfallkrankenhaus Berlin (UKB) hospital in Berlin, Germany February 29, 2008. REUTERS/Fabrizio Bensch /File Photo
LONDON: Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world.
Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs – something Roche aims to leverage, for example, with last month's US$2bil (RM7.81bil) purchase of Flatiron Health.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
